I'm Elizabeth Iorns, founder and CEO of Science Exchange, a marketplace for outsourced research and development, working with major pharmaceutical and science companies.

I'm the founder and CEO of Science Exchange, a marketplace for scientific collaboration where researchers can order experiments from the world's best labs.

I started Science Exchange to solve my own problem as a breast cancer researcher who was frustrated with the process of farming out experiments.

Science Exchange connects pharmaceutical companies with early-stage biotech firms, facilitating advancements in cancer biology and other areas. The application of artificial intelligence in the biological sector is leading to innovations in predicting drug efficacy and toxicity during the preclinical stage, which helps avoid clinical failures.

I started Science Exchange because I saw how scientific research was evolving and becoming more specialized and multidisciplinary, which made collaborations inefficient.

I recently announced that Science Exchange has raised a Series C round, which is a significant milestone for our company.

The decision to initiate the reproducibility initiative was a game-changer for Science Exchange, enhancing its branding and opening doors to pharmaceutical partnerships.

The biggest challenge for Science Exchange when it started was convincing the conservative pharmaceutical industry to use the platform.

In a hundred years, Science Exchange will continue to enable scientific breakthroughs by providing infrastructure for collaboration among researchers.